USPTO serial 87335893
TPU PHARMA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KETCHUM, BRENDAN J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TPU PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bret E. Field
Bret E. Field BOZICEVIC, FIELD & FRANCIS LLP201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY, CA 94065UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; non-medicated soaps for personal use; perfumery; essential oils; hair lotions | ACTIVE | — |
| 005 | Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical products, namely, analgesics | ACTIVE | — |
| 035 | Wholesale and retail store services and online wholesale and retail store services featuring pharmaceutical products and medical devices for storage, application and disposal of pharmaceutical preparations; Retail and wholesale store services and online retail and wholesale store services featuring pharmaceutical preparations, veterinary preparations, sanitary preparations, and medical supplies for storage, application and disposable of pharmaceutical preparations | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to pharmaceutical product evaluation, testing and inspection services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named TPU PHARMA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 7, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 7, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 12, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 11, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 11, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 24, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 24, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 30, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 28, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 28, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 30, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 26, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 26, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 26, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 27, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 25, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 25, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 25, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 24, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 20, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 20, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 20, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 31, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 5, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 5, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 16, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 26, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 26, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 26, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 26, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 26, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 20, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 19, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 24, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 24, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 22, 2017 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Feb 21, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 17, 2017 | NWAP | NEW APPLICATION ENTERED | — |